Authorization

Year-end Report 1 January - 31 December 2019

Q-linea signs global partnership with Thermo Fisher Scientific for commercialization of ASTar intensifies ahead of ASTar launchSTOCKHOLM, Feb. 13, 2020 /PRNewswire/ --Fourth quarter, 1 October-31 December 2019AAAAAAAAAAA

Net sales amounted to SEK 0.0 million (0.3).AAAAAAAAAAAA



The operating result totalled SEK -62.1 million (-39.0).AAAAAAAAAAAA



The result for the period amounted to SEK -62.0 million (-39.4).AAAAAAAAAAAA



Earnings per share before and after dilution amounted to SEK -2.71 (-2.33).AAAAAAAAAAA



Cash flow from operating activities totalled SEK -52.1 million (-37.4).

Period, 1 January-31 December 2019AAAAAAAAAAA

Net sales amounted to SEK 1.0 million (1.1).AAAAAAAAAAAA



The operating result totalled SEK -179.1 million (-127.4).AAAAAAAAAAAA



The result for the period amounted to SEK -177.4 million (-128.4).AAAAAAAAAAAA



Earnings per share before and after dilution amounted to SEK -7.74 (-8.82).AAAAAAAAAAA



Cash flow from operating activities totalled SEK -169.8 million (-122.7).AAAAAAAAAAA



At 31 December 2019, cash and cash equivalents amounted to SEK 26.0 million (354.4), short-term investments in fixed-income funds and the current portion of long-term bonds to SEK 180.5 million (150.0) and investments in listed bonds to SEK 121.0 million (0).A

Significant events
in the fourth quarter of 2019AAAAAAAAAAA
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«     2022    »
 12
3456789
10111213141516
17181920212223
24252627282930
31